- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Kodak continues executive changes
Eastman Kodak continues to revamp its executive lineup. The Rochester,NY, film and PACS vendor announced several new personnel movesas part of the ongoing restructuring of its Health Sciences division(SCAN 10/11/95). Kodak has hired Camtronics veteran
Eastman Kodak continues to revamp its executive lineup. The Rochester,NY, film and PACS vendor announced several new personnel movesas part of the ongoing restructuring of its Health Sciences division(SCAN 10/11/95).
Kodak has hired Camtronics veteran Terence Rourke as directorof digital products marketing for cardiology. Kodak's cardiologyproducts unit manufactures cine films, processing chemicals andaccessories for the cardiac cath lab market.
Anne Robson has been named executive director of Kodak's healthcarebusiness and imaging group. Robson, who was previously the group'smarketing director, will manage all aspects of the unit, whichadvises health-care facilities on achieving operational efficiencies.She succeeds Richard Cimino, who is now general manager and vicepresident of the U.S. northeast region for Health Sciences.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
